Rheumatoid Arthritis

Dendright is commercializing an immune tolerizing immunotherapy for rheumatoid arthritis. Rheumatoid arthritis is an incurable disease affecting close to one percent of the population.

The liposome-based therapy for rheumatoid arthritis targets dendritic cells to “re-train” the body’s immune system’s response to an RA-specific antigen.

In models of rheumatoid arthritis, the liposome-based therapy has been shown to suppress the symptoms of disease.

Because the therapy targets the underlying cause of the disease, it has the potential to avoid common side effects of existing immunosuppressant drug therapies, such as infection susceptibility.